United Therapeutics Corporation (UTHR) Free Cash Flow Yield: 3.95%
Is United Therapeutics Corporation’s free cash flow yield high or low?
United Therapeutics Corporation's free cash flow yield of 3.95% is 32% below its 5-year average of 5.83%, near the low end of its 5-year range (3.61%–8.40%).
As of Saturday, June 13, 2026. 25.29% below its 12-month average of 5.29%.
UTHR Free Cash Flow Yield Chart
UTHR Average Free Cash Flow Yield Chart
UTHR Current vs Average Free Cash Flow Yield Chart
UTHR Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
3.95%
FREE CASH FLOW YIELD AVG TTM
5.29%
FREE CASH FLOW YIELD AVG 3Y
5.80%
FREE CASH FLOW YIELD AVG 5Y
5.83%
FREE CASH FLOW YIELD AVG 10Y
7.48%
FREE CASH FLOW YIELD AVG 15Y
7.11%
FREE CASH FLOW YIELD AVG 20Y
6.11%
CURRENT VS TTM AVG
-25.29%
CURRENT VS 3Y AVG
-31.84%
CURRENT VS 5Y AVG
-32.20%
CURRENT VS 10Y AVG
-47.19%
CURRENT VS 15Y AVG
-44.41%
CURRENT VS 20Y AVG
-35.37%
UTHR Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 3.95% | 5.29% | 5.80% | 5.83% |
| Waters Corporation (WAT) | $23.17B | 0.90% | 2.81% | 2.67% | 2.70% |
| BioNTech SE (BNTX) | $22.90B | 6.53% | 3.88% | 18.83% | 19.77% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 3.46% | 3.21% | 3.24% | 2.88% |
| Labcorp Holdings Inc. (LH) | $21.83B | 6.27% | 5.78% | 5.24% | 7.19% |
| Veeva Systems Inc. (VEEV) | $25.92B | 6.21% | 3.61% | 3.10% | 2.76% |
| Moderna, Inc. (MRNA) | $19.80B | N/A | 8.49% | 9.09% | 9.09% |
| DexCom, Inc. (DXCM) | $29.08B | 4.82% | 3.35% | 2.09% | 1.41% |
| Hologic, Inc. (HOLX) | $16.97B | 5.82% | 6.28% | 5.68% | 7.87% |
| Biogen Inc. (BIIB) | $29.53B | 8.83% | 9.18% | 6.94% | 6.70% |
Yield Comparison
FCF Yield
3.95%
Earnings Yield
4.96%
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
United Therapeutics Corporation Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Free Cash Flow Yield FAQ
- What is the free cash flow yield for United Therapeutics Corporation (UTHR)?
- The free cash flow yield for UTHR stock is 3.95%.
- Is United Therapeutics Corporation's free cash flow yield high or low?
- United Therapeutics Corporation's free cash flow yield of 3.95% is 32% below its 5-year average of 5.83%, near the low end of its 5-year range (3.61%–8.40%).
- What is the TTM average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The TTM average free cash flow yield for UTHR stock is 5.29%.
- What is the 3Y average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The 3Y average free cash flow yield for UTHR stock is 5.80%.
- What is the 5Y average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The 5Y average free cash flow yield for UTHR stock is 5.83%.
- What is the 10Y average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The 10Y average free cash flow yield for UTHR stock is 7.48%.
- What is the 15Y average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The 15Y average free cash flow yield for UTHR stock is 7.11%.
- What is the 20Y average free cash flow yield for United Therapeutics Corporation (UTHR)?
- The 20Y average free cash flow yield for UTHR stock is 6.11%.
United Therapeutics Corporation Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-12 | 3.95% |
| 2026-06-11 | 3.95% |
| 2026-06-10 | 3.96% |
| 2026-06-09 | 3.90% |
| 2026-06-08 | 3.96% |
| 2026-06-05 | 3.92% |
| 2026-06-04 | 3.93% |
| 2026-06-03 | 3.92% |
| 2026-06-02 | 3.99% |
| 2026-06-01 | 3.96% |
| 2026-05-29 | 3.87% |
| 2026-05-28 | 3.83% |
| 2026-05-27 | 3.78% |
| 2026-05-26 | 3.72% |
| 2026-05-22 | 3.79% |
| 2026-05-21 | 3.81% |
| 2026-05-20 | 3.82% |
| 2026-05-19 | 3.80% |
| 2026-05-18 | 3.80% |
| 2026-05-15 | 3.79% |
| 2026-05-14 | 3.74% |
| 2026-05-13 | 3.72% |
| 2026-05-12 | 3.70% |
| 2026-05-11 | 3.78% |
| 2026-05-08 | 3.81% |
| 2026-05-07 | 3.79% |
| 2026-05-06 | 3.61% |
| 2026-05-05 | 3.80% |
| 2026-05-04 | 3.74% |
| 2026-05-01 | 3.81% |
| 2026-04-30 | 3.80% |
| 2026-04-29 | 3.81% |
| 2026-04-28 | 3.82% |
| 2026-04-27 | 3.83% |
| 2026-04-24 | 3.83% |
| 2026-04-23 | 3.79% |
| 2026-04-22 | 3.78% |
| 2026-04-21 | 3.79% |
| 2026-04-20 | 3.79% |
| 2026-04-17 | 3.69% |
| 2026-04-16 | 3.74% |
| 2026-04-15 | 3.76% |
| 2026-04-14 | 3.76% |
| 2026-04-13 | 3.76% |
| 2026-04-10 | 3.80% |
| 2026-04-09 | 3.78% |
| 2026-04-08 | 3.74% |
| 2026-04-07 | 3.84% |
| 2026-04-06 | 3.88% |
| 2026-04-02 | 3.85% |
| 2026-04-01 | 3.81% |
| 2026-03-31 | 3.66% |
| 2026-03-30 | 3.69% |
| 2026-03-27 | 4.16% |
| 2026-03-26 | 4.08% |
| 2026-03-25 | 4.01% |
| 2026-03-24 | 4.08% |
| 2026-03-23 | 4.17% |
| 2026-03-20 | 4.14% |
| 2026-03-19 | 4.12% |
| 2026-03-18 | 4.10% |
| 2026-03-17 | 4.02% |
| 2026-03-16 | 4.07% |
| 2026-03-13 | 4.05% |
| 2026-03-12 | 4.08% |
| 2026-03-11 | 3.99% |
| 2026-03-10 | 4.06% |
| 2026-03-09 | 4.11% |
| 2026-03-06 | 4.54% |
| 2026-03-05 | 4.48% |
| 2026-03-04 | 4.43% |
| 2026-03-03 | 4.36% |
| 2026-03-02 | 4.23% |
| 2026-02-27 | 4.31% |
| 2026-02-26 | 4.31% |
| 2026-02-25 | 4.06% |
| 2026-02-24 | 5.01% |
| 2026-02-23 | 5.00% |
| 2026-02-20 | 5.01% |
| 2026-02-19 | 4.94% |
| 2026-02-18 | 4.98% |
| 2026-02-17 | 4.92% |
| 2026-02-13 | 5.01% |
| 2026-02-12 | 4.98% |
| 2026-02-11 | 4.99% |
| 2026-02-10 | 5.01% |
| 2026-02-09 | 5.01% |
| 2026-02-06 | 4.89% |
| 2026-02-05 | 4.95% |
| 2026-02-04 | 4.91% |
| 2026-02-03 | 4.96% |
| 2026-02-02 | 4.99% |
| 2026-01-30 | 5.05% |
| 2026-01-29 | 5.07% |
| 2026-01-28 | 5.08% |
| 2026-01-27 | 4.98% |
| 2026-01-26 | 5.01% |
| 2026-01-23 | 5.06% |
| 2026-01-22 | 5.03% |
| 2026-01-21 | 5.05% |
| 2026-01-20 | 5.07% |
| 2026-01-16 | 5.10% |
| 2026-01-15 | 5.03% |
| 2026-01-14 | 4.99% |
| 2026-01-13 | 4.98% |
| 2026-01-12 | 4.92% |
| 2026-01-09 | 4.91% |
| 2026-01-08 | 4.83% |
| 2026-01-07 | 4.71% |
| 2026-01-06 | 4.72% |
| 2026-01-05 | 4.84% |
| 2026-01-02 | 4.78% |
| 2025-12-31 | 4.87% |
| 2025-12-30 | 4.78% |
| 2025-12-29 | 4.72% |
| 2025-12-26 | 4.68% |
| 2025-12-24 | 4.61% |
| 2025-12-23 | 4.65% |
| 2025-12-22 | 4.62% |
| 2025-12-19 | 4.59% |
| 2025-12-18 | 4.68% |
| 2025-12-17 | 4.64% |
| 2025-12-16 | 4.74% |
| 2025-12-15 | 4.74% |
| 2025-12-12 | 4.80% |
| 2025-12-11 | 4.85% |
| 2025-12-10 | 4.89% |
| 2025-12-09 | 4.98% |
| 2025-12-08 | 4.95% |
| 2025-12-05 | 4.85% |
| 2025-12-04 | 4.90% |
| 2025-12-03 | 4.93% |
| 2025-12-02 | 5.00% |
| 2025-12-01 | 4.94% |
| 2025-11-28 | 4.88% |
| 2025-11-26 | 4.86% |
| 2025-11-25 | 4.88% |
| 2025-11-24 | 4.97% |
| 2025-11-21 | 5.00% |
| 2025-11-20 | 5.00% |
| 2025-11-19 | 4.98% |
| 2025-11-18 | 4.98% |
| 2025-11-17 | 5.03% |
| 2025-11-14 | 5.09% |
| 2025-11-13 | 5.13% |
| 2025-11-12 | 5.14% |
| 2025-11-11 | 5.17% |
| 2025-11-10 | 5.22% |
| 2025-11-07 | 5.28% |
| 2025-11-06 | 5.22% |
| 2025-11-05 | 5.30% |
| 2025-11-04 | 5.42% |
| 2025-11-03 | 5.41% |
| 2025-10-31 | 5.32% |
| 2025-10-30 | 5.23% |
| 2025-10-29 | 5.21% |
| 2025-10-28 | 5.34% |
| 2025-10-27 | 5.27% |
| 2025-10-24 | 5.30% |
| 2025-10-23 | 5.20% |
| 2025-10-22 | 5.26% |
| 2025-10-21 | 5.25% |
| 2025-10-20 | 5.13% |
| 2025-10-17 | 5.12% |
| 2025-10-16 | 5.13% |
| 2025-10-15 | 5.13% |
| 2025-10-14 | 5.12% |
| 2025-10-13 | 5.04% |
| 2025-10-10 | 5.04% |
| 2025-10-09 | 4.98% |
| 2025-10-08 | 4.94% |
| 2025-10-07 | 4.85% |
| 2025-10-06 | 4.89% |
| 2025-10-03 | 4.89% |
| 2025-10-02 | 5.00% |
| 2025-10-01 | 5.06% |
| 2025-09-30 | 5.29% |
| 2025-09-29 | 5.22% |
| 2025-09-26 | 5.13% |
| 2025-09-25 | 5.21% |
| 2025-09-24 | 5.05% |
| 2025-09-23 | 5.11% |
| 2025-09-22 | 5.35% |
| 2025-09-19 | 5.31% |
| 2025-09-18 | 5.41% |
| 2025-09-17 | 5.49% |
| 2025-09-16 | 5.57% |
| 2025-09-15 | 5.50% |
| 2025-09-12 | 5.47% |
| 2025-09-11 | 5.48% |
| 2025-09-10 | 5.59% |
| 2025-09-09 | 5.49% |
| 2025-09-08 | 5.62% |
| 2025-09-05 | 5.54% |
| 2025-09-04 | 5.83% |
| 2025-09-03 | 5.67% |
| 2025-09-02 | 5.48% |
| 2025-08-29 | 7.28% |
| 2025-08-28 | 7.22% |
| 2025-08-27 | 7.26% |
| 2025-08-26 | 7.17% |
| 2025-08-25 | 7.26% |
| 2025-08-22 | 7.10% |
| 2025-08-21 | 7.14% |
| 2025-08-20 | 7.24% |
| 2025-08-19 | 7.08% |
| 2025-08-18 | 7.06% |
| 2025-08-15 | 7.08% |
| 2025-08-14 | 7.11% |
| 2025-08-13 | 7.16% |
| 2025-08-12 | 7.36% |
| 2025-08-11 | 7.38% |
| 2025-08-08 | 7.35% |
| 2025-08-07 | 7.41% |
| 2025-08-06 | 7.33% |
| 2025-08-05 | 7.27% |
| 2025-08-04 | 7.58% |
| 2025-08-01 | 7.54% |
| 2025-07-31 | 8.07% |
| 2025-07-30 | 7.86% |
| 2025-07-29 | 7.81% |
| 2025-07-28 | 7.79% |
| 2025-07-25 | 7.63% |
| 2025-07-24 | 7.58% |
| 2025-07-23 | 7.60% |
| 2025-07-22 | 7.79% |
| 2025-07-21 | 7.92% |
| 2025-07-18 | 7.96% |
| 2025-07-17 | 7.81% |
| 2025-07-16 | 7.79% |
| 2025-07-15 | 7.92% |
| 2025-07-14 | 7.80% |
| 2025-07-11 | 7.86% |
| 2025-07-10 | 7.73% |
| 2025-07-09 | 7.73% |
| 2025-07-08 | 7.89% |
| 2025-07-07 | 8.00% |
| 2025-07-03 | 7.89% |
| 2025-07-02 | 7.87% |
| 2025-07-01 | 7.98% |
| 2025-06-30 | 8.08% |
| 2025-06-27 | 8.17% |
| 2025-06-26 | 8.18% |
| 2025-06-25 | 8.12% |
| 2025-06-24 | 8.01% |
| 2025-06-23 | 8.11% |
| 2025-06-20 | 7.99% |
| 2025-06-18 | 7.96% |
| 2025-06-17 | 8.10% |
| 2025-06-16 | 8.05% |
| 2025-06-13 | 8.20% |
| 2025-06-12 | 8.12% |
| 2025-06-11 | 8.40% |
| 2025-06-10 | 8.25% |
| 2025-06-09 | 7.07% |
| 2025-06-06 | 7.13% |
| 2025-06-05 | 7.26% |
| 2025-06-04 | 7.17% |
| 2025-06-03 | 7.16% |
| 2025-06-02 | 7.13% |
Showing the most recent 260 of 4,450 data points. The chart above shows the full history.
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt